Crinetics COO James Hassard departs; consulting deal through Jan 2025 at $200/hr

Crinetics Pharmaceuticals, Inc.

James Hassard ceased as COO effective Oct 14, 2024; consulting and separation agreements signed Oct 10.
Consulting agreement: up to 20 hrs/month at $200/hr through Jan 15, 2025 for commercial launch prep.
Separation agreement provides payments/benefits for termination without cause per employment contract.
Outstanding equity awards continue to vest through Jan 15, 2025; prior employment agreement terminated.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

James Hassard

Chief Operating Officer

CRNX · Crinetics Pharmaceuticals, Inc.

Effective: 2024-10-14
Filed: October 16, 2024, 7:59 PM ET

James Hassard ceased serving as the Chief Operating Officer of the Company, effective October 14, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Hassard departed as Chief Operating Officer at Crinetics Pharmaceuticals, Inc..

Action: ceased serving
Role: Chief Operating Officer

Exact text from the filing

James Hassard ceased serving as the Chief Operating Officer of the Company, effective October 14, 2024.

View on SEC.gov

Crinetics Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-238120

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.